Lupus Trial, Recruiting (NCT05567198)

Lupus Trial, Recruiting NCT05567198 Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Condition: Lupus

Printed from Voxsanity (voxsanity.com.au) — NCT05567198 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lupus

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women with lupus (SLE) who were under 40 years old when they started cyclophosphamide (CYC) treatment, and who did not receive a hormone-protecting injection called GnRH-a alongside it (Group 1)
Women with lupus (SLE) who were under 40 years old when they started cyclophosphamide (CYC) treatment, and who did receive leuprolide acetate (a GnRH-a injection, given either monthly or every 3 months) alongside it (Group 2)
Women with lupus (SLE) of a similar age who have never received cyclophosphamide (CYC) treatment, with or without GnRH-a, and who have no history of reproductive disorders, infertility, or untreated sexually transmitted infections (Control Group)

Who may not be able to join:

Women who were 40 years old or older at the time cyclophosphamide (CYC) treatment began (applies to Groups 1 and 2)
Women with a past or current history of reproductive disorders, infertility, or untreated sexually transmitted infections (applies to all groups)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sarfaraz A Hasni, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phone: (301) 451-1599

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05567198

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phase: Not Applicable

Status: Recruiting

Condition: Lupus

Trial contact: (301) 451-1599

More information: https://clinicaltrials.gov/study/NCT05567198

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women with lupus (SLE) who were under 40 years old when they started cyclophosphamide (CYC) treatment, and who did not receive a hormone-protecting injection called GnRH-a alongside it (Group 1)
Women with lupus (SLE) who were under 40 years old when they started cyclophosphamide (CYC) treatment, and who did receive leuprolide acetate (a GnRH-a injection, given either monthly or every 3 months) alongside it (Group 2)
Women with lupus (SLE) of a similar age who have never received cyclophosphamide (CYC) treatment, with or without GnRH-a, and who have no history of reproductive disorders, infertility, or untreated sexually transmitted infections (Control Group)

Who may not be able to join:

Women who were 40 years old or older at the time cyclophosphamide (CYC) treatment began (applies to Groups 1 and 2)
Women with a past or current history of reproductive disorders, infertility, or untreated sexually transmitted infections (applies to all groups)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Registry

ClinicalTrials.gov

Start date

3 March 2023

Est. completion

31 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

POI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov